Page last updated: 2024-08-23

etoposide and oblimersen

etoposide has been researched along with oblimersen in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	3 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Edelman, MJ; Hoffman, PC; Karnauskas, R; Kozloff, M; Rudin, CM; Szeto, L; Tomek, R; Vokes, EE	1
Klasa, RJ	1
Green, M; Hodgson, LD; Masters, GA; Rudin, CM; Salgia, R; Vokes, EE; Wang, X	1

Reviews

1 review(s) available for etoposide and oblimersen

Article	Year
Targeting the proapoptotic factor Bcl-2 in non-Hodgkin's lymphoma. Oncology (Williston Park, N.Y.), 2004, Volume: 18, Issue:13 Suppl 1 Topics: Alemtuzumab; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Gene Expression Regulation, Leukemic; Humans; Lymphoma, Non-Hodgkin; Oligonucleotides, Antisense; Prednisone; Proto-Oncogene Proteins c-bcl-2; Remission Induction; Rituximab; RNA, Messenger; Survival Analysis; Thionucleotides; Transplantation, Heterologous; Vincristine	2004

Article

Year

Targeting the proapoptotic factor Bcl-2 in non-Hodgkin's lymphoma.

Oncology (Williston Park, N.Y.), 2004, Volume: 18, Issue:13 Suppl 1

Topics: Alemtuzumab; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Gene Expression Regulation, Leukemic; Humans; Lymphoma, Non-Hodgkin; Oligonucleotides, Antisense; Prednisone; Proto-Oncogene Proteins c-bcl-2; Remission Induction; Rituximab; RNA, Messenger; Survival Analysis; Thionucleotides; Transplantation, Heterologous; Vincristine

2004

Trials

2 trial(s) available for etoposide and oblimersen

Article	Year
Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Mar-15, Volume: 22, Issue:6 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Disease-Free Survival; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Oligonucleotides, Antisense; Proto-Oncogene Proteins c-bcl-2; Survival Rate; Thionucleotides; United States	2004
Randomized phase II Study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Feb-20, Volume: 26, Issue:6 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Disease-Free Survival; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Odds Ratio; Thionucleotides; Treatment Outcome	2008

Article

Year

Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Mar-15, Volume: 22, Issue:6

Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Disease-Free Survival; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Oligonucleotides, Antisense; Proto-Oncogene Proteins c-bcl-2; Survival Rate; Thionucleotides; United States

2004

Randomized phase II Study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Feb-20, Volume: 26, Issue:6

Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Disease-Free Survival; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Odds Ratio; Thionucleotides; Treatment Outcome

2008